Australia's medical community is keenly observing the emergence of retatrutide, a dual GIP and GLP-1 receptor agonist . The novel treatment, currently undergoing clinical trials , demonstrates significant potential https://katrinasfli901351.ampedpages.com/a-new-breakthrough-for-weight-loss-70767054